North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

August 2020 | 116 pages | ID: N6CFF2C21578EN
GMD Research

Abstracts

North America antibiotics market is expected to grow by 2.3% annually in the forecast period and reach $14.67 billion by 2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Highlighted with 26 tables and 56 figures, this 116-page report “North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cephalosporin
• Penicillin
• Macrolides
• Fluoroquinolones
• Quinolones
• Monobactam
• Aminoglycosides
• Carbapenem
• Other Drug Classes

Based on Action Mechanism, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Oral Administration
• Intravenous Administration
• Other Administration Routes

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

• U.S.
• Canada
• Mexico

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY DRUG CLASS

3.1 Market Overview by Drug Class
3.2 Cephalosporin
3.3 Penicillin
3.4 Macrolides
3.5 Fluoroquinolones
3.6 Quinolones
3.7 Monobactam
3.8 Aminoglycosides
3.9 Carbapenem
3.10 Other Drug Classes

4 SEGMENTATION OF NORTH AMERICA MARKET BY ACTION MECHANISM

4.1 Market Overview by Action Mechanism
4.2 Cell Wall Synthesis Inhibitors
4.3 Mycolic Acid Inhibitors
4.4 RNA Synthesis Inhibitors
4.5 DNA Synthesis Inhibitors
4.6 Protein Synthesis Inhibitors
4.7 Other Mechanisms

5 SEGMENTATION OF NORTH AMERICA MARKET BY DRUG ORIGIN

5.1 Market Overview by Drug Origin
5.2 Natural Antibiotics
5.3 Semi-synthetic Antibiotics
5.4 Synthetic Antibiotics

6 SEGMENTATION OF NORTH AMERICA MARKET BY ACTIVITY SPECTRUM

6.1 Market Overview by Activity Spectrum
6.2 Broad-spectrum Antibiotics
6.3 Narrow-spectrum Antibiotics

7 SEGMENTATION OF NORTH AMERICA MARKET BY ROUTE OF ADMINISTRATION

7.1 Market Overview by Route of Administration
7.2 Oral Administration
7.3 Intravenous Administration
7.4 Other Administration Routes

8 SEGMENTATION OF NORTH AMERICA MARKET BY DRUG TYPE

8.1 Market Overview by Drug Type
8.2 Brand Antibiotics
8.3 Generic Antibiotics

9 NORTH AMERICA MARKET 2019-2030 BY COUNTRY

9.1 Overview of North America Market
9.2 U.S.
9.3 Canada
9.4 Mexico

10 COMPETITIVE LANDSCAPE

10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

11 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT

11.1 Risk Evaluation of North America Market
11.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of North America Antibiotics Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in North America Antibiotics Market
Table 3. North America Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 4. North America Antibiotics Market by Action Mechanism, 2019-2030, $ mn
Table 5. North America Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 6. North America Antibiotics Market by Activity Spectrum, 2019-2030, $ mn
Table 7. North America Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 8. North America Antibiotics Market by Drug Type, 2019-2030, $ bn
Table 9. North America Antibiotics Market by Country, 2019-2030, $ bn
Table 10. U.S. Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 11. U.S. Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 12. U.S. Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 13. Canada Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 14. Canada Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 15. Canada Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 16. Mexico Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 17. Mexico Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 18. Mexico Antibiotics Market by Route of Administration, 2019-2030, $ mn
Table 20. Abbott Laboratories: Company Snapshot
Table 21. Abbott Laboratories: Business Segmentation
Table 22. Abbott Laboratories: Product Portfolio
Table 23. Abbott Laboratories: Revenue, 2016-2018, $ mn
Table 24. Abbott Laboratories: Recent Developments
Table 25. Risk Evaluation for Investing in North America Market, 2019-2030
Table 26. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. North America Antibiotics Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of North America Antibiotics Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of North America Antibiotics Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Antibiotics Market
Figure 13. Breakdown of North America Antibiotics Market by Drug Class, 2019-2030, % of Revenue
Figure 14. North America Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)
Figure 15. North America Antibiotics Market: Cephalosporin, 2019-2030, $ mn
Figure 16. North America Antibiotics Market: Penicillin, 2019-2030, $ mn
Figure 17. North America Antibiotics Market: Macrolides, 2019-2030, $ mn
Figure 18. North America Antibiotics Market: Fluoroquinolones, 2019-2030, $ mn
Figure 19. North America Antibiotics Market: Quinolones, 2019-2030, $ mn
Figure 20. North America Antibiotics Market: Monobactam, 2019-2030, $ mn
Figure 21. North America Antibiotics Market: Aminoglycosides, 2019-2030, $ mn
Figure 22. North America Antibiotics Market: Carbapenem, 2019-2030, $ mn
Figure 23. North America Antibiotics Market: Other Drug Classes, 2019-2030, $ mn
Figure 24. Breakdown of North America Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue
Figure 25. North America Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)
Figure 26. North America Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn
Figure 27. North America Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn
Figure 28. North America Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 29. North America Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 30. North America Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn
Figure 31. North America Antibiotics Market: Other Mechanisms, 2019-2030, $ mn
Figure 32. Breakdown of North America Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue
Figure 33. North America Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)
Figure 34. North America Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn
Figure 35. North America Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn
Figure 36. North America Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn
Figure 37. Breakdown of North America Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue
Figure 38. North America Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)
Figure 39. North America Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn
Figure 40. North America Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn
Figure 41. Breakdown of North America Antibiotics Market by Route of Administration, 2019-2030, % of Revenue
Figure 42. North America Addressable Market Cap in 2020-2030 by Route of Administration, Value ($ mn) and Share (%)
Figure 43. North America Antibiotics Market: Oral Administration, 2019-2030, $ mn
Figure 44. North America Antibiotics Market: Intravenous Administration, 2019-2030, $ mn
Figure 45. North America Antibiotics Market: Other Administration Routes, 2019-2030, $ mn
Figure 46. Breakdown of North America Antibiotics Market by Drug Type, 2019-2030, % of Revenue
Figure 47. North America Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)
Figure 48. North America Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn
Figure 49. North America Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn
Figure 50. Breakdown of North America Antibiotics Market by Country, 2019 and 2030, % of Revenue
Figure 51. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 52. U.S. Antibiotics Market, 2019-2030, $ bn
Figure 53. Rising Incidence of Infectious Disease in U.S.
Figure 54. Canada Antibiotics Market, 2019-2030, $ bn
Figure 55. Antibiotics Market in Mexico, 2015-2030, $ bn
Figure 56. Growth Stage of North America Antibiotics Industry over the Forecast Period

COMPANIES MENTIONED

Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.